INTRODUCTION
============

Effective B cell responses are essential for host defense against pathogens, particularly in case of a viral infection, via the generation of neutralizing or opsonizing antibodies; however, excessive B cell responses can also be detrimental in case of autoimmunity. For instance, elevated autoantibodies in circulation have been associated with various systemic autoimmune diseases such as systemic lupus erythematosus, Sjögren's syndrome and rheumatoid arthritis ([@b44-bt-25-130]; [@b40-bt-25-130]). The existence of autoantibodies indicates insufficient immune tolerance to self-reactive B cells in the patients. Given that a large fraction of autoantibodies are IgG isotypes, it is evident that auto-reactive T helper cells are also involved in the development of autoantibodies. Among diverse helper T cell subsets, follicular helper T (Tfh) cells are tightly associated with autoantibodies in humans with systemic autoimmune diseases ([@b10-bt-25-130]; [@b42-bt-25-130]).

Tfh cells play crucial roles in germinal center reactions to exogenous antigens as well as to self-antigens in autoimmunity ([@b10-bt-25-130]; [@b42-bt-25-130]; [@b43-bt-25-130]). Tfh cells induce clonal expansion of B cells, affinity maturation and isotype class switching of antibodies and subsequent differentiation of B cells into long-lived plasma cells or memory B cells. Tfh cells are characterized by high expression of CXCR5, which enables primed T cells to emigrate from T cell zone to B cell follicles when it is accompanied by simultaneous downregulation of CCR7 ([@b1-bt-25-130]; [@b17-bt-25-130]; [@b18-bt-25-130]; [@b6-bt-25-130]). The generation of Tfh cells requires interaction with B cells as well as ICOS, CD28, and CD40L signals ([@b18-bt-25-130]; [@b30-bt-25-130]; [@b9-bt-25-130]; [@b45-bt-25-130]). In addition, IL-6, IL-21 and IL-27 are known to drive Tfh cell differentiation from naïve precursors via the activation of STAT3 ([@b30-bt-25-130]; [@b12-bt-25-130]; [@b3-bt-25-130]). These signal 2 and signal 3 likely drive the expression of two transcription factors Bcl-6 and Ascl2 to complete the Tfh cell commitment ([@b20-bt-25-130]; [@b31-bt-25-130]; [@b48-bt-25-130]; [@b25-bt-25-130]).

CD4^+^ T cells expressing Foxp3 are essential for maintaining immune tolerance to self-antigens ([@b26-bt-25-130]). Mutation in Foxp3 causes detrimental systemic autoimmune responses as shown in scurfy mice as well as IPEX syndrome in humans ([@b39-bt-25-130]). Recent studies by independent researchers confirm that there are at least four functional subsets in Foxp3^+^ T regulatory (Treg) cells that specifically inhibit Th1, Th2, Th17, and Tfh cell responses, respectively ([@b5-bt-25-130]). Among them, Treg cells expressing CXCR5 and Bcl6, named T follicular regulatory (Tfr) cells, appear to be located in the B cell follicles to control germinal center reactions. Tfr cells are originated from thymic Treg cells, and their development depends on CD28, CD40L as well as ICOS costimulation in addition to Bcl6 ([@b8-bt-25-130]; [@b24-bt-25-130]; [@b47-bt-25-130]; [@b37-bt-25-130]). Of note, decreased Tfr cells are associated with increased autoantibodies in animal models of lupus. For instance, BXD2 mice that spontaneously develop antibodies to dsDNA and histone exhibit reduced ratio of Tfr cells to Tfh cell or to germinal center B cells ([@b21-bt-25-130]). More importantly, adoptive transfer of Tfr cells significantly ameliorates the development of lupus in BXD2 mice ([@b11-bt-25-130]), indicating that malfunction of Tfr cells can trigger autoimmune B cell responses *in vivo*. In addition, a recent human study found that contraction of Tfr cells was inversely correlated with expansion of Tfh cells in the peripheral blood of IPEX patients ([@b7-bt-25-130]). Therefore, these studies collectively propose that the use of Tfr cells might be a promising therapeutic approach for the treatment of autoimmunity associated with increased autoantibodies.

Using Treg cells for the prevention and/or treatment of immune disorders has been investigated in experimental animals as well as in clinical setting in humans ([@b33-bt-25-130]). A number of clinical studies conducted with Treg cells are currently awaiting FDA approval for clinical use in graft-versus-host disease (GVHD) after bone marrow transplantation, as well as autoimmune diseases such as type 1 diabetes (T1D), Crohn's disease and multiple sclerosis ([@b41-bt-25-130]). Despite their strong immune suppressive activity, there are a few limitations that need to be addressed for the optimal therapeutic efficacy of Treg cell-based immunotherapy. Firstly, the antigen specificity of Treg cells is likely important for the therapeutic efficacy; however, it is difficult to obtain antigen-specific Treg cells in case of autoimmunity, although there has been some progress in expanding allo-reactive Treg cells in case of GVHD. Secondly, the functional specificity of Treg cell subsets should be considered in the preparation of therapeutic Treg cells. For instance, use of Tfr cells is likely far more effective than pooled Treg cells consisting of diverse Treg cell subsets in suppressing an autoreactive germinal center reaction. This is because Tfr cells efficiently migrate into B cell follicles while the other Treg cell subsets fail to do so due to lack of CXCR5 on their surface. Thirdly, the stability of Treg cells should be fully explored since Treg cells are known to be converted into non-Treg cells, especially in response to inflammatory cytokines *in vivo* ([@b49-bt-25-130]; [@b28-bt-25-130]; [@b38-bt-25-130]; [@b22-bt-25-130]). Hence, the application of stable and functionally relevant Treg cell subsets with known antigen-specificity would be ideal for the development of efficacious immunotherapy with minimal adverse effects.

Although the use of Tfr cells can be efficacious for the treatment of antibody-mediated immune disorders, obtaining sufficient number of Tfr cells is an obvious obstacle for the development of such Treg-cell therapy. The reason for that is because it only consists of \~5--10% of Treg cells which is only \~10% of CD4^+^ T cells ([@b8-bt-25-130]; [@b24-bt-25-130]; [@b47-bt-25-130]). In the present study, we aimed to investigate whether CXCR5 transduction onto Treg cells endows Tfr cell-like properties. We found that *Cxcr5-*transduction mediated stable expression of CXCR5 on Treg cells *in vitro* as well as *in vivo*. These *Cxcr5*-transduced Treg cells retained potent immunosuppressive activity against conventional T cells. In addition, *Cxcr5*-transduced Treg cells pre ferentially migrated in response to the CXCL13 gradient to suppress the production of antibodies from B cells *in vitro*.

MATERIALS AND METHODS
=====================

Mice
----

C57BL/6, Foxp3-IRES-mRFP (Foxp3^RFP^), B6.SJL (CD45.1^+^), and *Tcrb^−/\ −^* (TCRβ KO) mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). All mice were maintained in the specific pathogen-free facilities at the vivarium of the Institute of Molecular Medicine, the University of Texas Health Science Center at Houston (TX, USA). All animal experiments were performed using protocols approved by Institutional Animal Care and Use Committee of the University of Texas at Houston.

Antibodies and flow cytometry
-----------------------------

For cell sorting, lymphoid cells isolated from mouse spleens or draining lymph nodes, were obtained and stained with PerCp-Cy5.5-conjugated anti-CD4 (clone GK1.5, BioLegend, San Diego, CA, USA), Alexa488-conjugated anti-CD62L (clone MEL-14, BioLegend), PE-conjugated anti-CD25 (clone PC61, BioLegend), Alexa647-conjugated anti-CD44 (clone IM7, BioLegend), APC-conjugated anti-CD45R/B220 (clone RA3-6B2, BioLegend), Alexa488 anti-GL7 (clone GL7, BD Pharmingen, San Jose, CA, USA), PE-conjugated anti-IgD (clone 11-26c.2a, BioLegend), FITC-conjugated anti-CD279 (PD-1, clone J43, eBioscience, San Diego, CA, USA), Biotinconjugated anti-CXCR5 (clone L138D7, BioLegend), and APC-conjugated Streptavidin (BioLegend).

The stained cells were analyzed by FACSAria II (BD Bioscience, San Jose, CA, USA), and the data were analyzed using FlowJo software (TreeStar, Ashland, OR, USA).

Cell isolation and culture
--------------------------

CD4^+^ T cells and B220^+^ B cells were isolated by anti-CD4 and anti-CD45R microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), respectively. B220^+^GL7^--^IgD^+^ naïve B cells, and CD4^+^CD25^--^CD44^--^CD62L^+^ naïve T cells were isolated from pooled spleen and peripheral lymph nodes of naïve C57BL/6 mice. CD4^+^PD-1^+^CXCR5^+^ Tfh cells were isolated from the draining lymph nodes of mice immunized with KLH by FACSAria II. Treg cells isolated from Foxp3^RFP^ mice using Treg isolation kit (Miltenyi Biotec) were stimulated using Treg expansion kits (Miltenyi Biotec), according to the manufacturer's protocols with a small modification (50 U/ml of mIL-2, instead of 1000 U/ml).

Cells were cultured in RPMI 1640 medium (Lonza, Houston, TX, USA) supplemented with 10% FBS, 55 μM 2-mercaptoethanol, 2 mM L-glutamine, 100 units penicillin-streptomycin (all from Gibco, Carlsbad, CA, USA), and 10 μg/ml gentamicin (Sigma-Aldrich, St. Louis, MO, USA). 293T cells were cultured in DMEM medium (Lonza) supplemented with 10% FBS 4.5g/l glucose, 2 mM L-glutamine, and 100 units penicillin-streptomycin.

CXCR5 cloning and retroviral transduction
-----------------------------------------

Mouse *Cxcr5* cDNA PCR fragment was prepared using iProof High-Fidelity DNA polymerase (BIORAD, Hercules, CA, USA), with *Cxcr5* cloning primer sets (Forward 5′-ATCGAGATCTATGAACTACCCACTAACCCTGGAC-3′ and Reverse 5′-ATCGCTCGAGCTAGAAGGTGGTGAGGGAAGTAGC-3′). After *Bgl II* and *Xho I* (all from New England Biolabs, Beverly, MA, USA) enzyme digestion, the mCXCR5 fragment was ligated into the unique *BglII* and *XhoI* site of RVKM-IRES-*Gfp* vector (RV) using T4 ligase (Invitrogen, Carlsbad, CA, USA). 10 μg of pCL-Eco packaging vector with 10 μg of RV-empty vector or RV-*Cxcr5* were co-transfected into the 293T cells using calcium phosphate/chloroquine (100 μM, Sigma, St. Louis, MO, USA) method. Twenty four hours later, stimulated Treg cells were transduced with RV-empty vector or RV-*Cxcr5* in the presence of 8 μg/ml of polybrene (Sigma). Four days after the transduction, GFP and RFP double positive cells were sorted by FACSAria II (BD Bioscience, San Jose, CA, USA) for further approaches.

*In vitro* treg suppression assay
---------------------------------

Cell proliferation dye eFluor670 (eBioscience, 5 μM) labeled conventional CD4^+^ T cells (Tconv, 1.0×10^5^) isolated from congenic B6. SJL mice were co-cultured with indicated number of FACS-sorted GFP^+^RFP^+^ retrovirally transduced Treg cells in a round-bottomed 96-well plate in the presence of 0.5 μg/ml of anti-CD3 and irradiated (3000 cGy) T cell-depleted splenocytes (1.0×10^5^) for 3 days. The proliferation of the Tconv cells was measured based on eFluor670 dilution by the CD4^+^CD45.1^+^ cell population by flow cytometry.

*In vitro* cell migration assay
-------------------------------

FACS-sorted GFP^+^RFP^+^ retrovirally transduced Treg cells (3.0×10^5^) were rested at 37°C for 2 hours in complete RPMI media. Cells were placed in the upper chamber \[(Corning, Corning, NY, USA), Polycarbonate, 6.5 mm diameter, 5 μm pore size\] containing 100 μl of complete RPMI media. The lower chamber was filled with 600 μl complete RPMI media containing various concentrations of CXCL13 (PeproTech, Rocky Hill, NJ, USA). After 4 hours of incubation, cells from the lower chamber were collected and the cell count was determined by running samples at a fixed flow rate (60 μl/min) for 1 min by FACS Calibur (BD Bioscience, San Jose, CA, USA). Migration index was calculated as follows: ((number of migrated cells/number of input cells)\*100).

*In vitro* co-culture assay
---------------------------

RV-empty vector or RV-*Cxcr5*-transduced Treg cells (1.5×10^4^) were placed in the upper chamber (Corning, Polycarbonate, 96 well, 3 μm pore size) containing 75 μl of complete RPMI media with the lower chamber containing 245 μl complete RPMI media with 1.5 μg/ml of CXCL13. After 1 hour of incubation, cells from the lower chamber were collected and co-cultured with B220^+^GL7^--^IgD^+^ (1.0×10^5^) naïve B cells and CD4^+^PD-1^+^CXCR5^+^ Tfh cells (3.0×10^4^) in the presence of 2.0 μg/ml soluble anti-CD3e (clone 145-2C11, BioXcell, West Lebanon, NH, USA) and anti-IgM (AffiniPure F(ab')~2~ Fragment Goat anti-IgM, μ chain specific, Jackson ImmunoResearch, West Grove, PA, USA) for 6 days. The levels of murine IgG in the culture supernatant were determined by enzyme-linked immunosorbent assay (ELISA).

Adoptive transfer studies and keyhole limpet hemocyanin (KLH) immunization
--------------------------------------------------------------------------

Wild-type or CXCR5^−/−^ Treg cells (CD4^+^CD25^hi^, 5.0×10^5^) were adoptively transferred into *Tcrb*^−^*^/^*^−^ mice together with CD25^−^GITR^−^CD62L^hi^CD44^lo^ naïve CD4^+^ T cells (3.0×10^6^). All recipient mice were s.c. immunized with KLH emulsified in CFA. Seven days later, the draining LNs were isolated and stained with PNA or anti-CD4 to visualize germinal center.

In some experiments, RV-empty vector or RV-Cxcr5-transduced Treg cells (5.0×10^5^) were adoptively transferred into *Tcrb*^−^*^/^*^−^ mice together with naïve CD4^+^ T cells isolated from B6.SJL mice (3.0×10^6^). The recipient mice were s.c. immunized with KLH in CFA, and lymphoid cells from the draining lymph nodes were collected and analyzed for the presence of CD45.2^+^GFP^+^RFP^+^ donor T cells.

Western blot analysis
---------------------

FACS-sorted RV-empty vector or RV-*Cxcr5*-transduced Treg cells were incubated in serum-free medium for overnight, then stimulated with indicated concentration of CXCL13 for 10 minutes. The cells were lysed in RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% Na deoxycholate, 0.1% SDS, and Protease/phosphatase inhibitors cocktail) and equal amounts of protein were electrophorated on Tris-Glycine NN 8--16% precast gel (NuSep Ltd., Frenchs Forest, Australia) and transferred onto polyvinylidene fluoride (PVDF) membranes. Western blot analysis was performed using the phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) rabbit monoclonal antibody and p44 MAP Kinase (Erk1) rabbit polyclonal antibody (both from Cell Signaling Technology, Danvers, MA, USA). The blots were incubated with horseradish peroxidase-conjugated donkey anti-rabbit IgG (sc-2313, Santa Cruz, Dallas, TX, USA) and detected with SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, Waltham, MA, USA).

Enzyme-linked immunosorbent assay (ELISA)
-----------------------------------------

To measure the levels of IgG produced by B cells *in vitro*, total murine IgG was quantified in culture supernatants with total IgG capture antibody (Donkey anti-mouse IgG (H+L), Jackson ImmunoResearch) and HRP-conjugated total IgG detection antibody (Goat anti-mouse IgG, SouthernBiotech, Birmingham, AB, USA).

Quantitative real-time RT-PCR
-----------------------------

Total RNA was extracted from retroviral vector transduced cells (3.0×10^5^ cells) with TRIzol (Invitrogen) and reverse transcribed using amfiRivert reverse transcriptase (GenDEPOT, Baker, TX, USA) according to the manufacturer's protocol. Gene expression was measured with iTaq-SYBR Green Supermix (BIORAD Laboratories, Hercules, CA, USA) and the ABI-PRISM 7900 detection system (Applied Biosystems, Foster City, CA, USA). Data were normalized to expression of the *Actb* gene.

Statistical analysis
--------------------

Data were analyzed with GraphPad Prism 5 (GraphPad, La Jolla, CA, USA). Statistics was calculated with the two-tailed Student's *t*-test. *p*-values below 0.05 were considered statistically significant.

RESULTS
=======

CXCR5-deficient treg cells are inefficient in controlling germinal center reactions
-----------------------------------------------------------------------------------

We and others previously demonstrated that follicular regulatory T cells (Tfr cells) expressing Foxp3 and CXCR5 regulates germinal center reactions ([@b8-bt-25-130]; [@b24-bt-25-130]). To confirm that CXCR5 expression in Foxp3^+^ Treg cells is essential for the regulation of germinal center formation, we adoptively transferred naïve CD4^+^ T cells together with WT or CXCR5-deficient Treg cells into *Tcrb*-deficient mice. One day after transfer, the recipient mice were subcutaneously immunized with keyhole limpet hemocyanin (KLH) emulsified in CFA. Seven days after immunization, we found an evident PNA^+^ germinal center formation in the draining lymph nodes ([Fig. 1](#f1-bt-25-130){ref-type="fig"}). Of note, we observed an increase in the size of PNA^+^ germinal centers in the lymph nodes of the CXCR5-deficient Treg cell recipients compared to those of WT Treg cell recipients ([Fig. 1](#f1-bt-25-130){ref-type="fig"}, upper panels). Consistently, CD4^+^ T cells in the germinal center, presumably Tfh cells, were observed in the lymph nodes of the former group ([Fig. 1](#f1-bt-25-130){ref-type="fig"}, lower panels). These results indicate that CXCR5 expression in Treg cells is required for Treg cell-mediated control of germinal center reactions.

Generation of CXCR5-expressing treg cells
-----------------------------------------

One of the key features of Tfr cells is its ability to emigrate into B cell follicles via CXCR5-mediated chemotaxis ([@b37-bt-25-130]). Therefore, we hypothesized that enforced expression of CXCR5 onto Foxp3^+^ Treg cells would endow the ability of preferential migration to B cell follicles in the secondary lymphoid organs in response to the CXCL13 gradient. As a first step to test this hypothesis, we first cloned mouse *Cxcr5* gene into a retroviral vector (RV) containing IRES and GFP. Foxp3^+^ Treg cells were isolated from *Foxp3-IRES-mRFP* (Foxp3^RFP^) reporter mice, which express a monomeric red fluorescence protein (mRFP) under the control of mouse *Foxp3* promoter. We then transduced RV-empty-*Gfp* vector (RV-empty) or RV-*Cxcr5-Gfp* vector (RV-*Cxcr5*) into the RFP^+^ Treg cells in the presence of TCR stimulation by anti-CD3 and anti-CD28 Abs ([Fig. 2A](#f2-bt-25-130){ref-type="fig"}). Four days after the retroviral transduction, surface expression of CXCR5 on Treg cells was analyzed by flow cytometry. As depicted in [Fig. 2B](#f2-bt-25-130){ref-type="fig"}, most of the RV-*Cxcr5*-transduced Treg cells expressed CXCR5 in a GFP intensity-dependent manner while few RV-empty vector-transduced Treg cells expressed CXCR5. Therefore, while anti-CD3/anti-CD28 stimulation alone failed to do so, retroviral transduction efficiently induced the upregulation of CXCR5 on the surface of Treg cells.

*Cxcr*5-transduced Treg cells maintain suppressive activity *in vitro*
----------------------------------------------------------------------

We next compared the expression of Treg cell-associated genes in the transduced cells. To this end, we purely isolated CD4^+^RFP^+^GFP^+^ Treg cells by flow cytometry four days after RV transduction using a sorting strategy described in [Fig. 3A](#f3-bt-25-130){ref-type="fig"}. As a result, we obtained \>95% of RFP^+^GFP^+^ Treg cells from each transduction condition. As expected, RV-*Cxcr5-*transduced Treg cells exhibited a significantly up-regulated *Cxcr5* transcript expression compared to RV-empty vector-transduced Treg cells. On the other hand, levels of Treg cell-associated gene transcripts, such as *Foxp3*, *Icos* and *Ctla4*, in Treg cells appeared to be comparable between the two cells ([Fig. 3B](#f3-bt-25-130){ref-type="fig"}). Moreover, RV-*Cxcr5*-transduced Treg cells were as potent as RV-empty vector-transduced Treg cells in suppressing the proliferation of naive CD4^+^ T cells in an *in vitro* suppression assay ([Fig. 3C](#f3-bt-25-130){ref-type="fig"}). These results together indicate that retroviral transduction of *Cxcr5* gene efficiently induces CXCR5 expression in Treg cells without affecting their suppressive function *in vitro*.

CXCR5 on the *Cxcr5*-transduced Treg cells is stable *in vivo*
--------------------------------------------------------------

Treg cells are known to be converted into conventional T cells in response to inflammatory cytokines by downregulating Foxp3 ([@b49-bt-25-130]; [@b22-bt-25-130]). Instability of Foxp3 expression is one of the concerns for the clinical application of Treg cells ([@b41-bt-25-130]). Therefore, we next sought to determine the stability of Foxp3 as well as CXCR5 in the transduced Treg cells *in vivo*. To this end, RFP^+^GFP^+^ Treg cells among the retrovirally transduced cells were isolated as shown in [Fig. 3A](#f3-bt-25-130){ref-type="fig"}, before being adoptively transferred into TCRβ-deficient mice. Naïve CD4^+^ T cells isolated from CD45.1^+^ congenic mice were co-transferred into the same recipients. The recipient mice were then subcutaneously immunized with KLH ([Fig. 4A](#f4-bt-25-130){ref-type="fig"}). Seven days later, we analyzed CD4^+^CD45.2^+^ T cells in the draining lymph nodes. As depicted in [Fig. 4B, 4C](#f4-bt-25-130){ref-type="fig"}, over 95% of the RV-*Cxcr5*-transduced as well as RV-empty-transduced donor T cells retained RFP expression, indicating that the transduced T cells maintained their Foxp3 expression *in vivo* even after active immunization. More importantly, about 60% of RV-*Cxcr5*-transduced CD4^+^RFP^+^GFP^+^ Treg cells expressed CXCR5, while only about 15% of RV-empty vector-transduced cells did so ([Fig. 4D, 4E](#f4-bt-25-130){ref-type="fig"}), indicating that the *Cxcr5*-transduced Treg cells remarkably maintained CXCR5 on their surface in the recipient mice *in vivo*. Collectively, according to this experimental setting, these results demonstrate that the expression of Foxp3 and CXCR5 was largely stable *in vivo*.

*Cxcr5*-transduced Treg cells efficiently migrate toward the CXCL13 gradient and suppress antibody production from B cell
-------------------------------------------------------------------------------------------------------------------------

We next determined if the *Cxcr5*-transduced Treg cells act like Tfr cells in terms of their migratory property as well as their B cell suppressive activity. CXCL13 is a chemokine enriched in B cell follicles whose receptor is CXCR5 ([@b15-bt-25-130]; [@b23-bt-25-130]). CXCL13 has been shown to activate Erk1/2 mitogen-activated protein kinase (MAPK) pathway upon stimulation via CXCR5 ([@b29-bt-25-130]). Therefore, we addressed whether CXCL13 activates the Erk1/2 signaling pathway in the RV-*Cxcr5*-transduced Treg cells. CD4^+^RFP^+^GFP^+^ cells isolated from retroviral vector-transduced Treg cells were stimulated with different concentrations of CXCL13 for 10 minutes. Then, we analyzed the phosphorylation of Erk1/2 by immunoblot. As depicted in [Fig. 5A](#f5-bt-25-130){ref-type="fig"}, CXCL13 stimulation induced an evident phosphorylation of Erk1/2 in the *Cxcr5-*transduced Treg cells in a dose-dependent manner, indicating that the CXCR5 on the transduced Treg cells was functional. By contrast, little phosphorylation of Erk 1/2 was detectable in the RV-empty vector-transduced Treg cells ([Fig. 5A](#f5-bt-25-130){ref-type="fig"}). We next determined whether the transduced Treg cells migrate toward the CXCL13 gradient by employing an *in vitro* tran-swell chemotaxis assay. While RV-empty vector-transduced Treg cells failed to migrate into the CXCL13-containing bottom well regardless of CXCL13 concentration in the transwell system, the RV-Cxcr5-transduced Treg cells efficiently migrated into the CXCL13-containing well in a dose-dependent manner ([Fig. 5B](#f5-bt-25-130){ref-type="fig"}). These results clearly demonstrate that CXCR5 on the RV-*Cxcr5*-transduced Treg cells was functionally active.

We finally determined whether the *Cxcr5*-transduced Treg cells control Tfh cell-mediated antibody production from B cell. To mimic a germinal center environment, we employed a transwell culture system. In brief, B220^+^GL7^--^IgD^+^ naïve B cells were co-cultured with FACS-sorted CD4^+^PD-1^+^CXCR5^+^ Tfh cells in the presence of soluble anti-CD3, anti-IgM, and CXCL13 to mimic germinal center reactions in the bottom well. FACS-sorted GFP^+^RFP^+^ cells from the RV-empty- or RV-*Cxcr5*-transduced Treg cell population were placed in the upper well. After 1 hour of incubation, the upper wells were removed and the bottom wells were further cultured for 6 days. As expected, Tfh cells efficiently stimulated B cells to produce IgG in the absence of Treg cells. However, adding RV-*Cxcr5-*transduced Treg cells into upper wells significantly inhibited IgG production from B cells while RV-empty-transduced Treg cells failed to do so ([Fig. 5C](#f5-bt-25-130){ref-type="fig"}). Taken together, in this experimental setting, these results suggest that stable expression of CXCR5 on the Treg cells by *Cxcr5* transduction drives chemotactic activity toward the CXCL13 gradient to suppress Tfh cell-mediated IgG production from B cells *in vitro* ([Fig. 5D](#f5-bt-25-130){ref-type="fig"}).

DISCUSSION
==========

In the present study, we aimed to determine if ectopic expression of CXCR5 on Treg cells can induce Tfr cell properties. We demonstrate that (i) CXCR5-deficient Treg cells were inefficient in suppressing germinal center reactions, (ii) retroviral transduction of *Cxcr5* did not affect the expression of Treg cell-related genes nor its suppressive activity, (iii) expression of CXCR5 and Foxp3 in the *Cxcr5*-transduced Treg cells was largely stable when transferred *in vivo*, (iv) CXCR5 on the *Cxcr5*-transduced Treg cells was functionally active, and (v) *Cxcr5*-transduced Treg cells sufficiently suppressed the production of IgG from B cells stimulated with Tfh cells in our transwell studies. Thus, the *Cxcr5*-transduced Treg cells resemble some features of Tfr cells including the expression of CXCR5 and the responsiveness toward the CXCL13 gradient as well as B cell suppressive activity. Therefore, our findings suggest that these genetically engineered Tfr-like cells might be a promising alternative to genuine Tfr cells which can be developed as novel cellular immunotherapeutics for the treatment of antibody-mediated immune disorders in humans.

Due to the low frequency of Treg cells in the peripheral blood of human patients, polyclonal Treg cells were expanded from precursor cells *ex vivo* by TCR stimulation or IL-2 cytokine stimulation or both for clinical application of Treg cells. In the current study, *Cxcr5*-transduced Treg cells were further expanded by TCR stimulation for four more days after retroviral transduction. It is possible that exogenous IL-2 can induce vigorous proliferation of *Cxcr5*-transduced Treg cells after transduction. Interestingly, however, it has been demonstrated that Stat5 activation by exogenous IL-2 inhibited Tfh cell development by promoting Blimp-1, a critical negative regulator of Bcl6 ([@b19-bt-25-130]; [@b32-bt-25-130]). Therefore, it needs to be tested if IL-2 can be used for the expansion of Cxcr5-transduced Treg cells *in vitro* without affecting the stability and function of Tfr cells.

Several preclinical studies proved that the inhibitory function of Ag-specific Treg cells is superior to that of polyclonal Treg cells in suppressing autoimmune diseases or graft rejection ([@b27-bt-25-130]). Ag-specific Treg cells were generally prepared by *ex vivo* expansion of precursor cells by antigenic stimulation. In the present study, however, it remains unclear whether the CXCR5-transduced Treg cells can suppress germinal center reactions in an antigen-specific manner *in vivo*, since we started with polyclonal Treg cells. Chimeric antigen receptor (CAR) technique has been emerged as a promising tool to generate T cells recognizing a specific antigen *ex vivo* ([@b13-bt-25-130]; [@b4-bt-25-130]). In particular, CAR has been extensively investigated for the last two decades in developiong Ag-specific T cell adoptive immunotherapy against cancer ([@b14-bt-25-130]; [@b16-bt-25-130]). CAR is a retrovirally transduced artificial T cell antigen receptor that consists of single-chain variable fragment (ScFv), hinge region, transmembrane domain, costimulatory domain and TCR ζ-chain ([@b14-bt-25-130]). It has been suggested that if the CAR can recognize tissue-specific antigens in the inflammed tissue, Treg cells can be activated *in vivo* without knowing the target autoantigens ([@b4-bt-25-130]). In this regard, we propose that the use of CAR technique will endow antigen-specificity into the engineered Treg cells. For instance, surface molecules expressed on resting or activated B cells, such as CD19 and GL7, would be attractive targets for the development of CAR-mediated Ag-specific Tfr adoptive immunotherapy.

There still reamins an issue with stability and persistence of the engineered Tfr cells for their clinical application. The stability of Treg cells *in vivo* has been a matter of debate for the last ten years. Several mouse studies have demonstrated that a small number of CD4^+^Foxp3^--^ "exFoxp3" T cells originated from Foxp3^+^ Treg cells contribute to the development of autoimmune diseases in diabetes or arthritis animal models ([@b49-bt-25-130]; [@b2-bt-25-130]; [@b22-bt-25-130]). On the contrary, others suggested that only a minor subset of Treg cells have potential to be pathogenic after losing Foxp3, while the majority of remaining Treg cells are stable *in vivo* ([@b34-bt-25-130]; [@b28-bt-25-130]). We found that *Cxcr5*-transduced Treg cells stably express Foxp3 as well as CXCR5 without converting to Tfh cells or other pathogenic non-Treg cells when transferred *in vivo*. But it needs to be addressed whether *Cxcr5*-transduced Treg cells stably express Foxp3 and persist in the long term under severe inflammatory settings like lupus-prone BXD2 mice ([@b21-bt-25-130]).

Compared to conventional Treg cells, Tfr cells highly express several costimulatory molecules including ICOS, PD-1, CTLA-4 and GITR ([@b8-bt-25-130]; [@b24-bt-25-130]; [@b47-bt-25-130]; [@b35-bt-25-130], [@b36-bt-25-130]; [@b46-bt-25-130]). In addition, increased Ki-67 expression reveals that Tfr cells have enhanced proliferative potential ([@b47-bt-25-130]; [@b35-bt-25-130]). These results suggest that Tfr cells represent not just the Treg cells that are selectively located in GC regions but they are activated Treg cells with enhanced suppressive activity. Recently, however, it has been shown that Tfr cells directly suppress B cells through CTLA4 and the suppressive activity of Tfr cells against B cells was comparable to that of conventional Treg cells ([@b36-bt-25-130]; [@b46-bt-25-130]). Since the suppressive mechanism by which Tfr cells inhibit B cells was similar to that by conventional Treg cells in those studies, we propose that *Cxcr5*-transduction itself might be sufficient to confer B cell suppressive Tfr-like activity on Treg cells as long as the Treg cells are properly activated during and after the transduction. Hence, careful consideration on Treg cell homing properties should be given when developing cellular immunotherapy based on Treg cells.

It still remains to be elucidated whether Tfr cells have unique characteristics other than CXCR5 expression that are essential for the regulation of the germinal center reaction. In this regard, Bcl6, a Tfh cell defining transcription factor, would be one of the attractive candidates for Tfr engineering to assure full differentiation of Tfr cells. Unfortunately, however, since Bcl6 transduction itself was not sufficient to induce CXCR5 expression in naïve T cells, it has been demonstrated that Bcl6 transduction alone could not initiate Tfh cell programing in naïve T cells ([@b9-bt-25-130]). A recent study demonstrated that achaete-scute homologue-2 (ASCL2) facilitates early Tfh differentiation by inducing upregulation of CXCR5 ([@b25-bt-25-130]). It will be interesting to test whether *Ascl2* transduction can ensure the generation of stable Tfr-like cells from conventional Treg cells without affecting Foxp3 expression and suppressive function.

In summary, we found that forced expression of CXCR5 endowed Tfr-like features in Treg cells. These engineered Tfr-like cells efficiently migrated along with CXCL13 gradient and effectively suppressed B cell antibody production. Our study provides new insights into the development of adoptive Treg cell immunotherapy for the regulation of autoimmune disorders.
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![CXCR5-dependent regulation of germinal center formation by Treg cells. Naïve CD4^+^CD25^--^GITR^--^CD62L^hi^CD44^lo^ T cells isolated from wild-type (WT) mice were mixed with CD4^+^CD25^hi^ Treg cells isolated from WT or CXCR5^−/−^ mice and adoptively transferred into *Tcrb*^−^*^/^*^−^ mice. Twenty four hours later, the recipient mice were s.c. immunized with KLH in CFA. Seven days after immunization, germinal center formation (PNA) and CD4^+^ T cell localization (CD4) in the draining lymph node of the recipient mice were analyzed. Dotted areas represent germinal centers.](bt-25-130f1){#f1-bt-25-130}

![Generation of CXCR5-expressing Treg cells. (A) Schematic representation of retroviral transduction of Treg cells. RFP^+^ Treg cells isolated from Foxp3-IRES-mRFP (Foxp3^RFP^) mice were retrovirally transduced with RV-empty vector or RV-*Cxcr5*-expressing vector. Retrovirally transduced Treg cells were further expanded in the presence of TCR stimulation for 4 days. CD4^+^RFP^+^GFP^+^ cells were sorted by flow cytometry. (B) Cell surface expression of CXCR5 in gated CD4^+^RFP^+^ cells was analyzed by flow cytometry. Numbers in the histogram indicate median fluoresence intensity (MFI) of CXCR5 expression in RV-empty (Dotted)- and RV-*Cxcr5* (Solid). Data are representatives of three independent experiments.](bt-25-130f2){#f2-bt-25-130}

![Retroviral transduction of *Cxcr5* on Treg cells does not affect Treg cell signature genes expression or their suppressive ability. (A) Cell sorting strategy and sorting purity of retrovirally transduced Treg cells. After five days of retroviral transduction, CD4^+^RFP^+^GFP^+^ cells were sorted by flow cytometry. (B) Quantitative RT-PCR analysis of indicated genes were conducted in RV-empty vector- or RV-*Cxcr5-*transduced Treg cells. Naïve CD4^+^ T cells were included as a control. (C) Cell proliferation dye-labeled responder conventional T cells (Tconv; CD4^+^CD25^--^ T cells) were stimulated with anti-CD3 Ab in the presence of irradiated T cell-depleted splenocytes for 3 days. Titrated number of RV-empty vector- or RV-*Cxcr5*-transduced Treg cells were added to the culture. Cell proliferation was measured by flow cytometry. Data are representatives of three independent experiments (^\*\*^*p\<*0.01).](bt-25-130f3){#f3-bt-25-130}

![CXCR5 expression in *Cxcr5*-transduced Treg cells is stable *in vivo*. (A) RV-empty vector- or RV-*Cxcr5*-transduced Treg cells were co-transferred with naïve CD4^+^ T cells isolated from B6.SJL congenic mice into *Tcrb*^−^*^/^*^−^ mice followed by subcutaneous immunization of the recipient mice with KLH. Seven days later, the transferred Treg cells in the draining lymph nodes were analyzed by flow cytometry after gating on CD4^+^CD45.2^+^GFP^+^ cells. (B, C) RFP expression in gated CD4^+^CD45.2^+^RFP^+^ were analyzed. (D, E) Flow cytometric analysis of CXCR5 expression in gated CD4^+^CD45.2^+^RFP^+^ cells. Data are representatives of two independent experiments (^\*\*^*p\<*0.01).](bt-25-130f4){#f4-bt-25-130}

![*Cxcr5*-transduced Treg cells can migrate in a CXCL13 dose-dependent manner and suppress antibody production by B cells *in vitro*. (A) Serum starved RV-empty vector- or RV-*Cxcr5*-transduced Treg cells were stimulated with titrated doses of CXCL13 for 10 mins. Phosphorylation of Erk1/2 was analyzed by Western blot. (B) Transwell migration of RV-empty vector- or RV-*Cxcr5*-transduced Treg cells to CXCL13-enriched lower chamber was analyzed. Titrated doses of CXCL13 were added to the lower chamber. (C) Cells recovered from lower chamber in (B) were co-cultured with B220^+^GL7^--^IgD^+^ naïve B cells and CD4 +PD-1^+^CXCR5^+^ Tfh cells in the presence of 2 μg/ml soluble anti-CD3ε and anti-IgM Abs for 6 days. Total IgG levels were measured by ELISA. (D) Illustration of the effect of *Cxcr5*-transduction on Treg cells for Treg cell signature gene expression and chemotaxis toward CXCL13. Data are representatives of two independent experiments (^\*^*p\<*0.05, ^\*\*\*^*p\<*0.001).](bt-25-130f5){#f5-bt-25-130}
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